Evergy Inc. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Evergy Inc. Common Stock trades at $83.25 (market cap $19.06B), while uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B). The key difference: Evergy Inc. Common Stock is far larger — about 13.1× uniQure N.V. Ordinary Shares's market cap, and Evergy Inc. Common Stock pays a 3.36% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Evergy Inc. Common Stock for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| EVRG | QURE | |
|---|---|---|
Market Cap | $19.06B | $1.45B |
Volume | 2,171,829 | 3,323,243 |
Sector | Utilities | Health |
52-Week High | $88.13 | $70.59 |
52-Week Low | $72.31 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $35.53B | $707.46M |
Dividend Yield | 3.36% | — |
Signals from Pluang's Aura AI — not financial advice
Evergy (EVRG) trades at $82.13, up 0.77% today, with a bullish technical signal and strong support near $80. The stock shows solid fundamentals with a P/E of 20.9 and net income margin of 15.19%, supported by recent earnings beats in Q1 and Q2 2026. Positive sentiment is driven by data center demand growth and a $21.6 billion investment plan, as highlighted in recent news.
The outlook for EVRG is positive, with analyst consensus pointing to a $89.83 price target and 38.89% buy ratings. Key opportunities include load growth from data center contracts and projected 6-8% EPS growth through 2030. Risks involve regulatory challenges, high capital expenditures, and potential volatility from interest rate sensitivity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Evergy is a regulated electric utility serving customers in Kansas and Missouri. Its operations include electricity generation, transmission, and distribution through its integrated utility subsidiaries.
Read more on EVRG →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →